PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline

New York, USA, June 20, 2023 (GLOBE NEWSWIRE) -- PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight

The prevalence of non-small cell lung cancer has been rising over the past few years, which prompts a growing demand for treatment options. The introduction of PD-1 cancer vaccines in non-small cell lung cancer with fewer side effects and increasing funding and government support towards the development of new drugs would drive the market of PD-1 cancer vaccines. The companies developing the potential therapies in the late stage of development include Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, and several others.

DelveInsight’s 'PD-1 Non-Small Cell Lung Cancer Pipeline Insight 2023' report provides comprehensive global coverage of pipeline PD-1 non-small cell lung cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the PD-1 non-small cell lung cancer pipeline domain.

Key Takeaways from the PD-1 Non-Small Cell Lung Cancer Pipeline Report

DelveInsight’s PD-1 non-small cell lung cancer pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for PD-1 non-small cell lung cancer treatment.
Key PD-1 non-small cell lung cancer companies such as Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New Age Pharmaceutical, Symphogen, and others are evaluating new PD-1 non-small cell lung cancer drugs to improve the treatment landscape.
Promising PD-1 non-small cell lung cancer pipeline therapies such as Ivonescimab, Zimberelimab, Dostarlimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, Lorigerlimab, RO 7247669, QL1706, F520, Sym021, and others are under different phases of PD-1 non-small cell lung cancer clinical trials.
In June 2023, Qilu Pharmaceutical presented trials in Progress poster presentation on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma (NSCLC) clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023).
In May 2023, Summit Therapeutics announced that the first United States-based patient has been enrolled in the Phase III HARMONi study. HARMONi is a Phase III multiregional, randomized, double-blinded study. The study will evaluate the efficacy and safety of ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) such as osimertinib.
In May 2023, Gilead Sciences and Arcus Biosciences announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) 50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. Progression-free survival curves showed early separation of both domvanalimab-containing arms from the zimberelimab arm, which was consistently maintained, and supports the potential therapeutic benefit of inhibiting the TIGIT pathway.
In October 2022, Akeso Biopharma announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation (BTD) for Ivonescimab (PD-1/VEGF bispecific antibody, AK112) combined with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients who failed to respond to prior PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.
In October 2022, GSK announced positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer. The safety and tolerability profile of dostarlimab in the PERLA phase II trial was consistent with previous clinical trials of similar regimens. The most common treatment-emergent adverse reactions were anemia, asthenia, nausea, constipation, cough, dyspnoea, vomiting, decreased appetite, and neutropenia.

Request a sample and discover the recent advances in PD-1 non-small cell lung cancer treatment drugs @ PD-1 Non-Small Cell Lung Cancer Pipeline Report

The PD-1 non-small cell lung cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage PD-1 non-small cell lung cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the PD-1 non-small cell lung cancer clinical trial landscape.

PD-1 Non-Small Cell Lung Cancer Overview

Lung cancer is a cancer that begins in the lungs. Cancer develops when cells in the body begin to proliferate uncontrollably. Non-Small Cell Lung Cancer accounts for 80% to 85% of all lung cancers. Non-Small Cell Lung Cancer is classified into three subtypes: adenocarcinoma, squamous cell carcinoma, and big cell carcinoma. Because their treatment and prognosis are typically similar, these subtypes, which begin in distinct types of lung cells, are classed together as Non-Small Cell Lung Cancer.

Some persons with non-small cell lung cancer can be treated with drugs that target these checkpoints. Immunotherapies targeting programmed death ligand 1 (PD-L1) and its receptor (PD-1) have increased survival in a subset of advanced lung cancer patients. PD-L1 protein expression has emerged as a biomarker for predicting which individuals may respond better to immunotherapy. The history of using several immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with distinct anti-PD-L1 and anti-PD-1 medicines complicates the understanding of PD-L1 as a biomarker.

Find out more about PD-1 non-small cell lung cancer treatment drugs @ Drugs for PD-1 Non-Small Cell Lung Cancer Treatment

A snapshot of the PD-1 Non-Small Cell Lung Cancer Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Ivonescimab	Summit Therapeutics	Phase III	Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor receptor antagonists	Intravenous
Zimberelimab	Arcus Biosciences	Phase III	Programmed cell death-1 receptor antagonists; T lymphocyte stimulants	Intravenous
Dostarlimab	GlaxoSmithKline	Phase II/III	Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonist	Intravenous
Sasanlimab	Pfizer	Phase II	Programmed cell death-1 receptor antagonists	Subcutaneous
Rilvegostomig	AstraZeneca	Phase I/II	Programmed cell death-1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors	Intravenous
SGN-PDL1V	Seagen	Phase I	Mitosis inhibitors; Programmed cell death-1 ligand-1 inhibitors; Tubulin polymerisation inhibitors	Intravenous

Learn more about the emerging PD-1 non-small cell lung cancer pipeline therapies @ PD-1 Non-Small Cell Lung Cancer Clinical Trials

PD-1 Non-Small Cell Lung Cancer Therapeutics Assessment

The PD-1 non-small cell lung cancer pipeline report proffers an integral view of the PD-1 non-small cell lung cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the PD-1 Non-Small Cell Lung Cancer Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Intravenous, Subcutaneous, Oral, Intramuscular
Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide
Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, Mitosis inhibitors, Tubulin polymerization inhibitors, Immunostimulants, Cell death stimulants, TIGIT protein inhibitors, Vascular endothelial growth factor receptor antagonists, T lymphocyte stimulants
Key PD-1 Non-Small Cell Lung Cancer Companies: Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New age Pharmaceutical, Symphogen, and others
Key PD-1 Non-Small Cell Lung Cancer Pipeline Therapies: Ivonescimab, Zimberelimab, Dostarlimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, Lorigerlimab, RO 7247669, QL1706, F520, Sym021, and others

Dive deep into rich insights for new drugs for PD-1 non-small cell lung cancer treatment, visit @ PD-1 Non-Small Cell Lung Cancer Drugs

Table of Contents

1.	PD-1 Non-Small Cell Lung Cancer Pipeline Report Introduction
2.	PD-1 Non-Small Cell Lung Cancer Pipeline Report Executive Summary
3.	PD-1 Non-Small Cell Lung Cancer Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	PD-1 Non-Small Cell Lung Cancer Clinical Trial Therapeutics
6.	PD-1 Non-Small Cell Lung Cancer Pipeline: Late-Stage Products (Pre-registration)
7.	PD-1 Non-Small Cell Lung Cancer Pipeline: Late-Stage Products (Phase III)
8.	PD-1 Non-Small Cell Lung Cancer Pipeline: Mid-Stage Products (Phase II)
9.	PD-1 Non-Small Cell Lung Cancer Pipeline: Early-Stage Products (Phase I)
10.	PD-1 Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
11.	Inactive Products in the PD-1 Non-Small Cell Lung Cancer Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the PD-1 Non-Small Cell Lung Cancer Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the PD-1 non-small cell lung cancer pipeline therapeutics, reach out @ PD-1 Non-Small Cell Lung Cancer Treatment Drugs

PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PD-1 non-small cell lung cancer companies, including AbbVie, BioNTech SE, Avistone Biotechnology Co., Ltd., Daiichi Sankyo, Inc., Arcus Biosciences, Inc., IO Biotech, Cellular Biomedicine Group, Inc., among others.

Non-Small Cell Lung Cancer Market

Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-small cell lung cancer companies, including Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, among others.

Non-Small Cell Lung Cancer Pipeline

Non-Small Cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, among others.

Small-cell Lung Cancer Pipeline

Small-cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.

Small Cell Lung Cancer Market

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, Advanced Accelerator Applications, Trillium Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, among others.

HER2-mutant Non-Small Cell Lung Cancer Pipeline

HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2-mutant non-small cell lung cancer companies, including Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, among others.

Other Trending Reports